CSBio CSBio

X
[{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Accelerates Development of COVID-19 Antiviral Treatment and Aims to Launch Rapid Self-testing Kit","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Doherty Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SK Bioscience and the Peter Doherty Institute for Infection and Immunity Join Forces Against Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            SK bioscience and the Doherty Institute will work to support and research in influenza biology, vaccines and antivirals. The program includes testing of anti-influenza compounds to identify new antivirals and development of quadrivalent cell culture-based influenza vaccine.

            Lead Product(s): Quadrivalent Cell Culture-based Influenza Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Vaccine

            Partner/Sponsor/Collaborator: Doherty Institute

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Celltrion achieved the first step of developing an antiviral treatment to fight COVID-19 and Plans to launch a fast self-testing diagnostic kit that could provide results within 15-20 minutes.

            Lead Product(s): Monoclonal antibody

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 23, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY